Skip to main content

Advertisement

Log in

OnabotulinumtoxinA in Pediatric Chronic Daily Headache

  • Headache (I Garza, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Chronic migraine occurs in about 3% of pediatric headaches. Many would be intractable to more than two preventive medications. OnabotulinumtoxinA has been approved by the US Food and Drug Administration for the use of chronic migraine in adults in 2010. Data on effectiveness and tolerability in the pediatric population are very limited. The study described in this article is a retrospective review of available data of all patients who received OnabotulinumtoxinA for chronic migraine in a large pediatric headache center from 2004 to 2010. Botox is recommended to any pediatric patient coming to the multidisciplinary clinic for chronic headache if they fail two or more preventive medications. This study showed a major change in the frequency of the headache with a statistical difference in the improvement of headache days per month. There was a 30-point drop in the pediatric disability scoring between first injection and follow-up injection with a change from severe disability to moderate disability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance

  1. Abu-Arefeh I, Russel G. Prevalence of headache and migraine in school children. BMJ (Clinical Research). 1994;309:765–9.

    Article  CAS  Google Scholar 

  2. •• Dodick W, Turkel C, DeGryse R, Aurora S, Silberstein S, Lipton R, Diener H. OnabotulinumtoxinA for Treatment of Chronic Migraine: Headache: The Journal of Head and Face Pain Volume 50, Issue 6, pages 921–936, June 2010 This is a review of the PREEMPT studies: double-blind placebo-controlled studies on the efficacy of BoNT-A in adults. The FDA approval for chronic migraine in adults was based on these studies.

    Article  Google Scholar 

  3. Bigal ME, Lipton RB, Tepper SJ, Rapoport AM, Sheftell FD. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology. 2004;63:843–7.

    PubMed  CAS  Google Scholar 

  4. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9–160.

    Google Scholar 

  5. •• Ahmed K, Hall Oa K, Mack K, Garza I. Experience with Botulinum Toxin Type A in Medically Intractable Pediatric Chronic Daily Headache. Pediatric Neurology.2010:43 (5), 316-319. This is a rare article describing expert opinion and experience on the use of BoNT-A in the pediatric population; the review is limited to 10 patients and is not a placebo-controlled study but is the only full published manuscript in pediatric use of BoNT-A. All previous submissions have been abstracts to different scientific meetings.

    Article  PubMed  Google Scholar 

  6. • Hershey AD, Powers S, Vockell AL, LeCates S, Kabbouche MA, Maynard MK. PedMIDAS: development of a questionnaire to assess disability of migraines in children. Neurology. 2001;57:2034–2039 This article describes the factors behind the disability scoring and assessment and is a major tool that is frequently used in clinical practice as well as in research in the pediatric population.

    PubMed  CAS  Google Scholar 

  7. Castillo J, Muñoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache. 1999;39:190–6.

    Article  PubMed  CAS  Google Scholar 

  8. Stang P, Osterhaus J. Impact of migraine in the United States: data from the National Health Interview Survey. Headache. 1993;33:29–35.

    Article  PubMed  CAS  Google Scholar 

  9. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:742–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

Conflicts of interest: M. Kabbouche: is a consultant for Allergan; H. O’Brien: has received grant support from the American Headache Society; Andrew D. Hershey: has board membership with the American Headache Society (travel to meetings); and has been a consultant for MAP Pharma and Allergan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marielle Kabbouche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kabbouche, M., O’Brien, H. & Hershey, A.D. OnabotulinumtoxinA in Pediatric Chronic Daily Headache. Curr Neurol Neurosci Rep 12, 114–117 (2012). https://doi.org/10.1007/s11910-012-0251-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-012-0251-1

Keywords

Navigation